Parasites and chronic renal failure

Reza Mohammadi Manesh¹, Ahmad Hosseini Safa¹, Seyedeh Maryam Sharafi², Rasool Jafari¹, Mehran Bahadoran¹, Morteza Yousefi¹, Hamid Nasri³, Hossein Yousofi Darani³

¹Department of Parasitology and Mycology, Isfahan University of Medical Sciences, Isfahan, Iran
²Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
³Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran

Abstract

Suppression of the human immune system results in an increase in susceptibility to infection by various infectious agents. Conditions such as AIDS, organ transplantation and chronic renal insufficiency (CRI) are the most important cause of insufficient immune response against infections. Long term renal disorders result in uremia, which can suppress human immune system. Parasitic infections are one of the most important factors indicating the public health problems of the societies. These infections can be more hostile and life threatening in susceptible individuals than in the normal people. In these patients some parasitic infections such as blastocystiosis, cryptosporidiosis and toxoplasmosis have been reported to be more prevalent. This review aimed to give an overview about parasitic infections in patients with renal disorders.

Introduction

By increasing the life expectancy among mankind population, subsequent incidence of some chronic diseases, such as chronic renal insufficiency (CRI) is increasing (1). CRI itself results some complications, in which renal function disturbs. When the renal function lost, body cannot sustain equilibrium of electrolytes. Consequently uremia may occur (2), which is the result of excess non-excreted metabolites accumulation, like urea (3). Natural state of immune-depression can cause by uremia and subsequent increase in the incidence of infections may happen (4,5). Around 48% of deaths in CRI patients are associated with these infections (2,6).

Also reduced immune response to various antigens, has been detected in patients with chronic kidney disease (CKD) who undergoing dialysis treatment (7-15). Additionally, it has been found that sepsis-related death is between 100 and 300-times more frequent in patients undergoing hemodialysis comparing to the general population (16). Intestinal parasitic infections have been considered as one of the major public health problems, predominantly in developing countries. However, because of some immunological conditions such as intentional suppression of immune response and also some immunodeficiencies in developed countries, some of these parasites have become a problematic issue (17). Chronic renal diseases are also one of the causes of insufficient immune response to the infections (2,18). Considering the important role of parasitic infections in creating complications or deaths in patients with renal problems, in this paper parasitic infections in patients with chronic renal disease is reviewed.

Intestinal parasites

There are lots of studies indicating higher prevalence of intestinal parasitic infections in patients with renal
disorders, which some are reviewed. From 2006 to 2007 hemodialysis patients of Campo Mourão city, Brazil were examined for Blastocystis sp. and other intestinal parasites and also the associated diarrhea. Thirty three (45.1%) out of 86 hemodialysis patients and 36 (25.7%) out of 146 control individuals were found to be infected by the parasites. The prevalence of intestinal parasitic infections in hemodialysis patients has been reported significantly higher than the healthy individuals. It is suggested that parasitological stool examinations, particularly for Cryptosporidium spp. and Blastocystis sp., are better to be perform in routine medical follow up examinations of hemodialysis patients (19).

In another study the prevalence of amoebiasis caused by Entamoeba histolytica/dispar in chronic hemodialysis patients has been reported to be about 8% (20). In Turkey a study carried out on patients with an end-stage renal failure and 150 healthy volunteers. Parasites were found in 62 (43.7%) out of 142 dialysis patients and 19 (12.7%) out of 150 healthy controls. The most prevalent cause of parasitic infection in the dialysis patients were Blastocystis sp. (23.9%), Giardia lamblia (8.5%), E. histolytica (2.1%), Microsporidia spp. (2.1%), and Cryptosporidium spp. (2.1%) (21). Intestinal parasitic infections were more prevalent in clinically asymptomatic renal transplant recipients than in patients with chronic haemodialysis and healthy individuals (22).

Study of Gill et al., in 2013, illustrated that 51.6% of hemodialysis patients were infected by intestinal parasites, but the prevalence of the infections in control group was 61.6%. Cryptosporidium antigen was observed only in patients with CKD (24.5%), but not in controls (23). They reported prevalence of 24.5% for cryptosporidiosis, which was considered to be high, even higher than some of the reports from renal transplant recipient patients (24) and livestock owners (25,26), which were at risk of infection. Their study indicated that patients with CKD were at risk of infection with Cryptosporidium spp. (23).

The prevalence of Cryptosporidium infection in patients with end-stage of chronic renal failure was investigated and compared to the healthy controls. Fifteen out of 174 patients with dialysis was positive for Cryptosporidium, while none of the controls had the infection. The reported prevalence was significantly higher in dialysis patients (27). In another study prevalence of Cryptosporidium infection among renal transplant recipients, patients referred to hemodialysis and the control group reported 34.8%, 25% and 17.4%, respectively (28). In the study carried out in Hamadan city, Iran, the prevalence of cryptosporidiosis has been reported 0.55% in renal transplanted patients, which is controversional to the previously mentioned studies (24). Also a very interesting report indicated that the prevalence of Cryptosporidium infection was 80% in patients with cancer, 25% in diabetics and 35% in dialysis patients (29), which are considerably higher than those in the reports from general population and diarrheic children (25,30).

In other studies 11.5% of renal transplant and 3.88% of hemodialysis patients were positive for Cryptosporidium infection. No positive results were found in the control groups (31).

Considering spore-forming protozoa, including Isospora bellii, Cryptosporidium parvum, Microsporidia and Cyclospora cayetanensis in patients with CKD, it has been reported that 33.3% of these patients were infected by these parasites (32). In another study, fecal samples of 104 chronic hemodialysis patients and 140 healthy controls were investigated for cryptosporidiosis. The prevalence of Cryptosporidium infection observed higher (11.5%) in dialysis patients compared to controls (3.6%) (33).

**Tissue parasites**

Anti-Toxoplasma IgG has been reported in 27.3% and 3.6% of 205 dialysis patients with renal insufficiency and 360 healthy controls, respectively (34). In another similar study, statistically significant higher prevalence has been observed for anti-Toxoplasma IgG and IgM seropositivity in hemodialysis patients than controls. So it has been recommended that hemodialysis patients should be tested for anti-Toxoplasma IgG and IgM using specific serological tests in order to prevent the disseminated infection (35). Other report showed that 36.8% of renal failure patients and 10.5% of normal population were seropositive for anti-Toxoplasma IgG and IgM. Also 56.7% and 16.7% of patients with regular hemodialysis and 69% and 24.1% of renal transplanted patients were seropositive for anti-Toxoplasma IgG and IgM, respectively (36). Higher rates of anti-Toxoplasma IgG and IgM, in renal transplanted and renal failure patients have also been reported (37,38). In another investigation significant higher sero-prevalence of toxoplasmosis has been reported in patients with chronic renal failure (38.3%) compared to the healthy controls (15%) (39).

In a study carried-out in Ahvaz city, southwest of Iran, 29.3% and 7.9% of hemodialysis patients and 26% and 4% of controls were seropositive for anti-Toxoplasma IgG and IgM, respectively (40). Also in other work the prevalence of anti-Toxoplasma gondii antibodies in 173 hemodialysis patients with CKD and 40 healthy controls were 56.06% and 1.73% for hemodialysis patients and 20% and 0% for healthy controls, respectively (41). Finally anti-Leishmania donovani antibodies among 1500 multiply transfused hemodialysis patients was (37%) and among 1194 volunteer blood donors was (9%) (42).

**Exoparasites**

Demodex folliculorum infestation has been detected in 25.53% of CKD patients and 18.42% of healthy controls (43). Also the D. folliculorum infection reported in 19.54% of dialysis patients and in 10.34% of healthy controls (44). The mean mite count in patients with infestation who were in end stage of renal failure was 6.12/cm² while in normal controls it was 0.31/cm² (45).

**Case reports about parasites in patients with renal disorders**

Case report studies about parasites in patients with renal disorders are summarized in Table 1.
Table 1. Parasites reported in hemodialysis patients in case report studies

| Parasite reported       | References         |
|-------------------------|--------------------|
| Strongyloides stercoralis| (46-48)            |
| Leishmania spp          | (49,50)            |

Conclusion

In conclusion, some parasitic diseases are considered as public health problems especially in developing countries (37,38,51,52). Patients with chronic kidney diseases are susceptible to be infected by some parasites such as Blastocystis sp., Cryptosporidium spp., and Toxoplasma gondii. Parasitic infections in these patients may make their situation much more complicated. Continues parasitological monitoring of patients with chronic renal failure is recommended for the possible control of the infections.

Authors’ contributions

All authors contributed the manuscript equally.

Ethical considerations

Ethical issues (including plagiarism, informed consent, misconduct, double publication and redundancy) have been completely observed by authors.

Conflict of interests

The authors declared no competing interests.

Funding/Support

None.

References

1. Lessa I, Mendonca GA, Teixeira MTB. [Noncommunicable chronic diseases in Brazil: from risk factors to social impact]. Boletín de la Oficina Sanitaria Panamericana (OSP) 1996;120(5):389-413.
2. Marques AB, Pereira DC, Ribeiro R. [Reasons and frequency of CRF patients' hospitalization in hemodialysis treatment]. Arq Ciênc Saúde 2005;12(2):67-72.
3. Levin A, Rocco M. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S12-154.
4. Kaufman CA, Manzler A, Phair J. Cell-mediated immunity in patients on long-term haemodialysis. Clin Exp Immunol 1975;22(1):54.
5. Dávila R, Guerra EMM, Rodrigues CIS, Fernandes FA, Cadaval RAM, Almeida FA. Sobrevivida de pacientes renais crônicos em diálise peritoneal e hemodiálise. J Bras Nefrol 1999;21(1):13-21.
6. Barbosa DA, Gunji CK, Bittencourt AR, Belasco AG, Diccini S, Vattimo F, et al. [Co-morbidity and mortality of patients in dialysis treatment]. Acta Paul Enferm 2006;19(3):304-9.
7. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Basic science and dialysis: disturbances of acquired immunity in hemodialysis patients. Paper presented at: Seminars in dialysis 2007.
8. Vanholder R, DeSmet R, Hsu C, Vogeleere P, Ringoir S. Uremic Toxins-the middle molecule hypothesis revisited. Paper presented at: Seminars in nephrology 1994.
9. Newberry WM, Sanford JP. Detectable cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest 1971;50(6):1262.
10. Schindler R, Linnenweber S, Schulze M, Oppermann M, Dinarello CA, Shaldon S, et al. Gene expression of interleukin-1β during hemodialysis. Kidney Int 1993;43(3).
11. Girnnt M, Heisel O, Köhler H. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrol Dial Transplant 1999;14(3):676-82.
12. Kaneko T, Osono E, Hayama N, Lino Y, Terashi A. T-cell activation modified by parathyroid hormone (PTH) in patients with end-stage renal disease. Clin Nephrol 1997;48(6):353-8.
13. Yang S, Smith C, Prahl JM, Luo X, Deluca HF. Vitamin D Deficiency Suppresses Cell-Mediated Immunity in Vivo. Arch Biochem Biophys 1993;303(1):98-106.
14. Giacchino F, Belardi P, Coppo R. Effects of blood transfusion on cellular immunity. Proc Eur Dial Transplant Assoc 1981;18:465-8.
15. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995;10(3):377-81.
16. Sarrak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000;58(4):1758-64.
17. Ferreira MS. Infections by protozoa in immunocompromised hosts. Memórias do Instituto Oswaldo Cruz 2000;95:159-62.
18. Eknoyan G, Levin NW. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl 1):S1-266.
19. Kulik RA, Falavigna DL, Nishi L, Araujo SM. Blastocystis sp. and other intestinal parasites in hemodialysis patients. Braz J Infect Dis 2008;12(4):338-41.
20. Ferreira-Filho SR, da Costa Braga FC, de Sa DM, Nunes EB, Parreira Soares JS, Padovese SM, et al. Entamoeba histolytica/Entamoeba dispar infection in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2011;22(2):237.
21. Karadag G, Tamer GS, Dervisoglu E. Investigation of intestinal parasites in dialysis patients. Saudi Med J 2013;34(7):714-8.
22. Esposito R, Orlando G, Inzoli C, Calello G, Moroni M, Rivolta E, et al. Asymptomatic parasitic infections in renal transplant recipients and in haemodialysis patients. Boll Ist Sieroter Milan 1986;66(3):210-3.
23. Gil FF, Barros MJ, Macedo NA, Júnior CG, Redoan R, Busatti H, et al. Prevalence of Intestinal Parasitism and Associated Symptomatology among Hemodialysis Patients. Rev Inst Med Trop Sao Paulo 2013;55(2):69-74.
24. Jafari R, Gharibi Z, Fallah M. The prevalence of cryptosporidium infection among renal transplanted patients in Hamadan city, West of Iran. Avicenna J Clin Microb Infect 2014;1(1):e19570.
Mohammadi Manesh R et al.

25. Jafari R, Maghsood AH, Fallah M. Prevalence of Cryptosporidium Infection among Livestock and Humans in Contact with Livestock in Hamadan District, Iran. 2012. J Res Health Sci 2012;13(1):86-89.

26. Jafari R, Maghsood AH, Safari M, Latifi M, Fallah M. Comparison of fecal antigen detection using enzyme linked immunosorbent assay (ELISA) with auramine-phenol staining method for diagnosis of human cryptosporidiosis. Jundishapur J Microbiol. In press.

27. Turkcapar N, Kutlay S, Nergizoglu G, Atli T, Duman N. Prevalence of Cryptosporidium infection in hemodialysis patients. Nephron 2002;90(3):344-6.

28. Chieffii PP, Sens YA, Paschoalotti MA, Miorin LA, Silva HGC, Jabur P. Infection by Cryptosporidium parvum in renal patients submitted to renal transplant or hemodialysis. Rev Soc Bras Med Trop 1998;31(4):333-7.

29. Baqai R, Anwar S, Kazmi S. Detection of cryptosporidium in immunosuppressed patients. J Ayub Med Coll Abbottabad 2005;17(3):38-40.

30. Fallah M, Haghighi A. Cryptosporidiosis in children with diarrhea referred to health centers in the west of Iran (hamedan). Med J Islam Repub Iran 1996;9(4):315-7.

31. Tappeh KH, Gharavi M, Makhoudi K, Rahbar M, Taghizadeh A. Prevalence of Cryptosporidium spp. Infection in Renal Transplant and Hemodialysis Patients. Iran J Public Health 2006;35(3):54-7.

32. Ali M, Mahmoud L, Abaza B, Ramadan M. Intestinal spore-forming protozoa among patients suffering from chronic renal failure. J Egypt Soc Parasitol 2000;30(1):93-100.

33. Seyrafi S, Pestehchian N, Kerdegari M, Yousefi Ha, Bastani B. Prevalence rate of Cryptosporidium infection in hemodialysis patients in Iran. Hemoal Int 2006;10(4):375-379.

34. Tong D, Yang J, Xu G, Shen G. [Serological investigation on Toxoplasma gondii infection in dialysis patients with renal insufficiency]. Zhongguo xue xi chong bing fang zhi za zhi 2011;23(2):144.

35. Ocak S, Duran N, Eskiocak AF, Aytaç H. Anti-Toxoplasma gondii antibodies in hemodialysis patients receiving long-term hemodialysis therapy in Turkey. Saudi Med J 2005;26(9):1378-82.

36. Auyf S, Mahgoub A, Saadi M, Adel EM. Serological detection of Toxoplasma gondii in chronic renal failure patients and renal transplant recipients. J Egypt Soc Parasitol 2009;39(3):943-50.

37. Jafari R, Sadaghian M, Safari M. Seroprevalence of Toxoplasma gondii Infection and Related Risk Factors in Tabriz City, Iran, 2008. J Res Health Sci 2012;12(2):119-21.

38. Rasouli S, Sadaghian M, Jafari R. Prevalence of human toxoplasmosis and related risk factors using Electrochemiluminescence (ECLIA) method in West Azerbaijan Province, Iran, 2010. Int J Biosci 2014;4(8):124-30.

39. Abbas M, Zaki M, Afify N. Prevalence of Toxoplasma gondii and cytomegalovirus antibodies in patients with chronic renal failure. J Egypt Soc Parasitol 1996;26(3):671-6.

40. Saki J, Khademvatan S, Soltani S, Shahbazian H. Detection of toxoplasmosis in patients with end-stage renal disease by enzyme-linked immunosorbent assay and polymerase chain reaction methods. Parasitol Res 2013;112(1):163-8.

41. Demirtaş F, Yaşlın Ş, Yaman O, Tokgöz B, Utaş C, Şahin İ. Anti-Toxoplasma gondii antibodies in haemodialysis patients with chronic renal failure. Yonsei Med J 2003;44(2):288-92.

42. Luz KG, da Silva VO, Gomes EM, Machado FC, Araujo MA, Fonseca HE, et al. Prevalence of anti-Leishmania donovani antibody among Brazilian blood donors and multiply transfused hemodialysis patients. Am J Trop Med Hyg 1997;57(2):168-71.

43. Özçelik S, Sümer Z, Değerli S. [The Incidence of Demodex folliculorum in Patients with Chronic Kidney Deficiency]. Türkiye Parazitol Derg 2007;31(1):66-8.

44. Yadgiran Düzgün O, Aytekin S. Comparison of Demodex folliculorum density in haemodialysis patients with a control group. J Eur Acad Dermatol Venereol 2007;21(4):480-83.

45. Karincaoglu Y, Esrefoglu Seyhan M, Bayram N, Aycan O, Taskapın H. Incidence of Demodex folliculorum in patients with end stage chronic renal failure. Ren Fail 2005;27(5):495-9.

46. Kosmadakis G, Georgoulia C, Filipoupolos V, Stefanou I, Smirloglou D, Michail S. Lethal Strongyloides stercoralis superinfection in an immunocompromised patient. Ren Fail 2010;32(6):750-2.

47. Said S, Nevez G, Moriniere P, Fournier A, Raccurt C. [Hemodialysis and strongyloidiasis: a presumed cause of eosinophilia able to mask the other]. Nephrologie 1998;20(6):343-6.

48. Hachim K, Mortajil F, Chakib A, Ramdani B, Zaïd D. [Severe angiulluliasis in a chronic haemodialysis patient]. Presse Med 2005;34(2 Pt 1):105-6.

49. Hussein MM, Mooij JM, Roujouleh HM, Hamour AO, Felemban H. Non-typhoid Salmonella septicemia and visceral leishmaniasis in a renal transplant patient. Transplantation 2001;71(3):479-81.

50. Maggi P, Larocca AM, Mininni F, Fiorentino G, Saracino AL, Chiornona M, et al. Autochthonous mucosal leishmaniasis in a hemodialyzed Italian patient. New Microbiol 2002;25(1):103-6.

51. Imani R, Khoshde A, Darani HY, Mobasher M. Comparative Clinical Trial of Mebendazole, Praziquantel and Metronidazole in Treatment of Human Giardiasis. J Res Health Sci 2012;12(2):119-21.

52. Yousofi Darani H. Situation of hydatid cyst infection during last two decades (1985-2005) in Iran. J Shahrekord Univ Med Sci 2008; 10: 78-88.